Hormonal regulation of serum lipoprotein (a) levels: Effects of parenteral administration of estrogen or testosterone in males

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 7, 1996, Pages 2633-2637

  Berglund, Lars ^a,b,d   Carlström, Kjell ^b   Stege, Reinhard ^b   Gottlieb, Claes ^b   Eriksson, Mats ^e   Angelin, Bo ^b   Henriksson, Peter ^c  

^a Columbia University ^*  (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Sodertalje Hospital   (Sweden)

^d The New York Presbyterian Hospital   (United States)

^e Coll Phys Surgs of Columbia Univ ^*

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; HORMONAL REGULATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY MECHANISM;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; ESTRADIOL; ESTRADIOL CONGENERS; HUMANS; INJECTIONS, INTRAMUSCULAR; LIPOPROTEIN(A); MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0029906321     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.7.2633     Document Type: Article

References (40)

1. Utermann, G. 1989 The mysteries of lipoprotein (a). Science. 246:904-910.
2. Scanu, AM. 1992 Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA. 267:3326-3329.
3. Berg K, Dahlén G, Frick MH. 1974 Lp(a) lipoprotein and pre-beta-1-lipoprotein in patients with coronary heart disease. Clin Genet. 6:230-235.
4. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto Jr AM. 1986 Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary heart disease documented by angiography. Circulation. 74:758-765.
5. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinci GB. 1981 Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 38:51-61.
6. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. 1992 Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentration. J Clin Invest. 90:52-60.
7. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. 1993 The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis. 101:61-68.
8. Rader DJ, Cain W, Ikewaki K, et al. 1994 The inverse relation of plasma lipoprotein (a) concentrations with apolipoprotein (a) isoform size is not caused by differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 93:2758-2763.
9. Brown SA, Hutchinson R, Morrisett J, et al. 1993 Plasma lipid, lipoprotein cholesterol and apoprotein distributions in selected US communities. The atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb. 13:1139-1158.
10. Berglund L. 1995 Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol. 6:48-56.
11. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. 1989 Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 84:802-810.
12. Henriksson P, Angelin B, Berglund L. 1992 Hormonal regulation of serum Lp(a) levels. Opposite effects of estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 89:1166-1171.
13. Soma MR, Osnago-Gadda I, Paoletti R, et al. 1993 The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 153:1462-1468.
14. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ. 1994 Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med. 123:837-841.
15. Seed M, Crook D. 1994 Postmenopausal hormonal replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol. 5:48-58.
16. Kushwaha R. 1992 Female sex steroid hormones and lipoprotein metabolism. Curr Opin Lipidol. 3:167-172.
17. Lobo RA. 1991 Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 73:925-930.
18. Sacks FM, Walsh BW. 1994 Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 5:236-240.
19. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. 1991 Effect of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1196-1204.
20. Moorjani S, Dupont A, Labrie F, et al. 1991 Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with urogestan in menopausal women. J Clin Endocrinol Metab. 73:373-379.
21. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. 1993 Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas. 17:191-196.
22. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH, Hazzard WR. 1984 Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 795:293-296.
23. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC. 1992 Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 92:41-47.
24. Henriksson P, Eriksson A, Stege R, et al. 1988 Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate. 13:257-261.
25. Carlson, K. 1973 Lipoprotein fractionation. J Clin Pathol. 26 Suppl: 5:32-37.
26. Södergård R, Bäckström T, Shanbag V, Carstensen H. 1982 Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature. J Steroid Biochem. 16:801-810.
27. Carlström K, Eriksson A, Custafsson SA, et al. 1985 Influence of orchidectomy or oestrogen treatment on serum levels of pregnancy associated alpha 2-glycoprotein and sex hormone binding globulin in patients with prostatic cancer. Int J Androl. 8:21-27.
28. Frazer AF, Narla G, Zhang JL, Rubin EM. 1995 The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet. 9:424-431.
29. Fåhreus L, Larsson-Cohn U, Ljungberg S, Wallentin L. 1984 Profound alterations of lipoprotein metabolism during danazol treatment in premenopausal women. Fertil Steril. 42:52-57.
30. Mälkönen M, Manninen V, Hirvonen E. 1980 Effects of danazol and lynestrenol on serum lipoproteins in endometriosis. Clin Pharmacol Ther. 28:602-604.
31. von Schoultz B, Carlström K, Collste L, et al. 1989 Estrogen therapy and liver function-metabolite effects of oral and parenteral administration. Prostate. 14:389-395.
32. Helgason S. 1982 Estrogen replacement after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand. [Suppl] 107:7-29.
33. Geola FL, Frumar AM, Tataryn IV, et al. 1980 Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab. 51:620-625.
34. El Makhzangy MN, Wynn V, Lawrence DM. 1979 Sex hormone binding globulin capacity as an index of oestrogenicity and androgenicity in women on oral contraceptive steroids. Clin Endocrinol (Oxf). 10:39-45.
35. Damber MG, Sandström B, von Schoultz B, Stigbrand T. 1979 A new and sensitive method for quantifying and comparing the biological potency of various estrogens in man. Acta Obstet Gynecol Scand. 58:527-530.
36. von Schoultz B. Potency of different oestrogen preparations. In: Studd J, Whitehead M, eds. The Menopause. London: Blackwell Scientific Publications; 130-137.
37. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Ȧ. 1988 Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 11:S101-S103.
38. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. 1990 Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol. 65:282-285.
39. Rannevik G, Carlström K, Doeberi A, Valentin L, Laurell C-B. 1996 Plasma protein changes induced by two orally administered androgen derivatives. Scand J Clin Lab Invest. 56:161-166.
40. von Schoultz B, Carlström K. 1989 On the regulation of sex hormone-binding globulin - a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem. 32:327-334.